Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
European Journal of Heart Failure|July 18, 2024
Safety and efficacy of aficamten in patients with non-obstructive hypertrophic cardiomyopathy: A 36-week analysis from FOREST-HCMAhmad Masri, Roberto Barriales-Villa, Perry Elliott, et al.
Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance|February 23, 2022
Sex-based differences in left ventricular remodeling in patients with chronic aortic regurgitation: a multi-modality studyAlbree Tower-Rader, Isadora Sande Mathias, Nancy A Obuchowski, et al.
Radiology. Cardiothoracic Imaging|April 4, 2024
Selective Use of CT Fractional Flow at a Large Academic Medical Center: Insights from Clinical Implementation after 1 Year of PracticeMangun K Randhawa, Angelo K Takigami, Vikas Thondapu, et al.
JACC. Cardiovascular Imaging|September 10, 2024
Mavacamten-Associated Temporal Changes in Left Atrial Function in Obstructive HCM: Insights From the VALOR-HCM TrialMilind Y Desai, Yuichiro Okushi, Kathy Wolski, et al.
Circulation|November 18, 2024
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCMMilind Y Desai, Kathy Wolski, Anjali Owens, et al.
JACC. Cardiovascular Imaging|September 16, 2025
Long-Term Favorable Cardiac Remodeling in Obstructive Hypertrophic Cardiomyopathy Patients Treated With Mavacamten for Up to 128 Weeks: Insights From the VALOR-HCM TrialMilind Y Desai, Yuichiro Okushi, Kathy Wolski, et al.
Circulation. Cardiovascular Imaging|September 2, 2024
Serial Changes in Ventricular Strain in Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Insights From the VALOR-HCM TrialMilind Y Desai, Yuichiro Okushi, Andrew Gaballa, et al.
JAMA Cardiology|August 28, 2023
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical TrialMilind Y Desai, Anjali Owens, Kathy Wolski, et al.
JACC. Heart Failure|April 26, 2025
Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic CardiomyopathyAhmad Masri, Martin S Maron, Theodore P Abraham, et al.
European Heart Journal|March 4, 2026
Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term studyAlbree Tower-Rader, Ahmad Masri, Michael E Nassif, et al.
Pageof 5